EI
LJPC

EAM Investors’s La Jolla Pharmaceutical Company LJPC Stock Holding History

EAM Investors’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-47,557
Closed -$1.65M – 397
2017
Q3 		$1.65M Buy
47,557
+25,327
+114% +$814K 0.22% 221
2017
Q2 		$662K Sell
22,230
-4,093
-16% -$117K 0.11% 239
2017
Q1 		$786K Buy
+26,323
New +$672K 0.12% 228
2016
Q4 		– Sell
-35,977
Closed -$856K – 427
2016
Q3 		$856K Buy
+35,977
New +$678K 0.12% 268
2016
Q1 		– Sell
-28,870
Closed -$779K – 408
2015
Q4 		$779K Sell
28,870
-68,480
-70% -$1.87M 0.1% 297
2015
Q3 		$2.71M Buy
+97,350
New +$3.07M 0.43% 78
2015
Q2 		– Sell
-97,003
Closed -$1.77M – 443
2015
Q1 		$1.77M Buy
97,003
+939
+1% +$19K 0.21% 209
2014
Q4 		$1.77M Buy
+96,064
New +$1.14M 0.25% 188
2014
Q2 		– Sell
-149,143
Closed -$1.61M – 433
2014
Q1 		$1.61M Buy
+149,143
New +$1.46M 0.29% 135

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's LJPC Position: Q4 2017 in Review

EAM Investors sold out of La Jolla Pharmaceutical Company (LJPC) in Q4 2017, closing a stake of 47,557 shares — an estimated $1.65M sold.

EAM Investors first reported a position in LJPC in Q1 2014 and held it in 9 quarters. The position peaked at $2.71M in Q3 2015. 93 funds tracked by Wall St. Rank hold LJPC as of Q4 2017.

  • EAM Investors reported no remaining La Jolla Pharmaceutical Company position as of Q4 2017 after selling out during the quarter.
  • EAM Investors sold 47,557 La Jolla Pharmaceutical Company shares in Q4 2017, an estimated $1.65M.
  • EAM Investors first reported a position in La Jolla Pharmaceutical Company in Q1 2014 and held it in 9 quarters.
  • EAM Investors's La Jolla Pharmaceutical Company position peaked at $2.71M in Q3 2015.
  • 93 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q4 2017.

Based on EAM Investors's 13F filing for Q4 2017, filed 12 Feb 2018.